Dermfree Wart Corn Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of warts and corns.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. An optional step includes soaking the wart in warm water for approximately 5 minutes to enhance the effectiveness of the treatment. After washing, the area must be dried completely.

If necessary, the medicated plaster can be cut to appropriately fit the size of the wart. The plaster should then be applied directly to the wart. This application should be repeated every 48 hours as needed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use is contraindicated on irritated, infected, or reddened skin due to the potential for exacerbation of the condition. Application is also contraindicated on genital warts or warts located on the face, as well as on moles, birthmarks, or warts with hair growing from them, to prevent adverse reactions. Additionally, the product should not be applied to mucous membranes, as this may lead to irritation or other complications.

Warnings and Precautions

The product is intended for external use only. It is imperative that healthcare professionals advise patients to avoid ingestion. In the event of accidental swallowing, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay.

Patients should be monitored for any signs of discomfort following application. If discomfort persists, it is recommended that the use of the product be discontinued.

Side Effects

For external use only. Patients should discontinue use if discomfort persists. It is advised that individuals with diabetes or poor blood circulation consult a doctor prior to use.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Dermfree Wart Corn Remover (salicylic acid 40% wart corn remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There is no specific information regarding the use of DERMFREE WART CORN REMOVER (salicylic acid 40% wart corn remover patch) during pregnancy. The drug insert does not provide safety concerns, dosage modifications, or special precautions for pregnant patients. Therefore, healthcare professionals should exercise caution when considering the use of this product in pregnant women, as the potential risks to fetal outcomes are not well characterized. It is advisable to weigh the benefits against any unknown risks when treating women of childbearing potential.

Lactation

Nursing mothers should consult a healthcare professional before using this product. There is a potential for excretion in breast milk; therefore, caution is advised when administering to lactating mothers. The effects on the nursing infant are not well studied; it is recommended to monitor for any adverse reactions in the infant.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted in these patients to ensure safety and therapeutic effectiveness.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary significantly depending on the substance involved and the individual patient’s characteristics. Symptoms may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate assessment of the patient's condition is critical. Recommended actions include:

1. Assessment and Monitoring: Conduct a thorough evaluation of the patient's vital signs and mental status. Continuous monitoring may be necessary to detect any deterioration in the patient's condition.

2. Supportive Care: Initiate supportive measures as required, which may include airway management, oxygen supplementation, intravenous fluids, and other interventions tailored to the patient's needs.

3. Toxicology Consultation: Consider consulting a poison control center or a toxicologist for guidance on specific management strategies, including the use of antidotes if applicable.

4. Reporting: Document the incident and report any adverse effects or overdose cases to the appropriate regulatory authorities as per local guidelines.

Healthcare professionals are encouraged to familiarize themselves with the specific management protocols for the substances they are prescribing or administering, as well as to stay updated on any new information regarding potential overdosage risks and management strategies.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to inform patients that the product should not be applied to irritated, infected, or reddened skin, as well as to genital warts, warts on the face, moles, birthmarks, or warts with hair growing from them, and on mucous membranes.

Patients should be counseled to monitor for any persistent discomfort following the use of the product and to report this to their healthcare provider. Additionally, it is crucial to instruct patients to avoid contact with the eyes or face. In the event that the product comes into contact with the eyes, they should rinse thoroughly with water.

Healthcare providers should also recommend that patients consult a doctor if they have diabetes or poor blood circulation, as these conditions may affect the use of the product.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within the temperature range of 59°F to 86°F (15°C to 30°C) to maintain its efficacy and integrity. Proper storage conditions should be observed to ensure optimal performance.

Additional Clinical Information

The medication is administered topically and may be repeated every 48 hours as needed, for a duration of up to 12 weeks. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Dermfree Wart Corn Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)